All News
Primary CNS vasculitis: what else causes vessel wall enhancement on dedicated brain MRI?
From Dr. Hajj-Ali https://t.co/v5ZtyezX3x
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
At the Global Rheum Summit, patients called for care that values people, not just disease.
✅ Respect lived experience
✅ Enable shared decisions
✅ Support education & coordination of care decisions.
@RheumNow #ACR25
Jiha Lee JihaRheum ( View Tweet)
~1 in 6 pts with #sarcoidosis May have #cardiac involvemt
1/3 respond to #MTX + #steroids
Followed by repeat #PET
Failures get
👇
#infliximab >#adalimumab
👇
#JAKi
Better survival >yrs ago
R heart involved ⬆️risk of MTX nonresponse
#ACR25 @RheumNow @ACRheum abst#1664 #ACRbest https://t.co/kYt9JRNSVH
Links:
Janet Pope Janetbirdope ( View Tweet)
In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either:
- during 1y of treatment
- in 2y follow-up
https://t.co/gtzNiSmutb
but StopRA will give us plenty of insights - data is never wasted
#ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX
Links:
David Liew drdavidliew ( View Tweet)
SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data:
safety profiles very similar, except for:
- zoster
- CK rise
- lymphopenia
- hepatic disorder
In the general RA population, no new JAKi safety signals
#ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa
David Liew drdavidliew ( View Tweet)
#ACR25 Please find our Day 1 Recap of the conference where we discussed our favourite abstracts and learning points 😃 @Janetbirdope @AurelieRheumo @RheumNow https://t.co/X125tjyqi5
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstract 1421: PsA and 'Brain Fog'
Pts w/ #PsA who did not achieve Minimal Disease Activity (MDA) had higher odds of subjective cognitive decline vs those with MDA
🔹 Fatigue, and to a lesser extent depression/anxiety, ↓ this associated risk
@RheumNow #ACR25 https://t.co/RohwKJZDzp
Links:
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
In the IMPACT trial (Abs 0855), certolizumab met its primary endpoint: <20% had an adverse pregnancy outcome (APO) among females w/ APS & prior APO.
✅ 94% live births, all survived to discharge
📈 Median GA: 37 wks (no APO) vs 31 wks (APO)
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Start strong, stay strong.
With early anti-TNF induction (vs csDMARD T2T)
- At 5 yrs: D2T RA in <1% vs 7% (OR 0.11, p=0.03)
Drug-free remission 13% vs 6% (p=0.049)
- At 10 yrs: more sustained remission (62% vs 45%) & fewer multi-MoA failures.
@RheumNow #ACR25 Abstract #1677
Jiha Lee JihaRheum ( View Tweet)
What is the secret of a VNS RCT that works in RA?
=> Implant the device!
RESET-RA RCT Sham controlled 3mo
Then open label in active arm for 66mo
40% pts IR to >=3 bioDMARDs
ACR 20 3 mo 42% vs. 19%
CDAI LDA 27% vs. 11%
82% TNF IR pt had no change in treatment over 12mo
99% https://t.co/lfxa4YXUB4
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study)
- 82% off b/tsDMARDs at 12mo
- also with benefit to control group after crossover at 3mo to an active device
#ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF
David Liew drdavidliew ( View Tweet)
Did we need a 2nd Interception RCT of HCQ in Pre-RA?
Unsure but in any case, it does not work either
STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO
36 months RA conversion
Dr Deane's take: "probably wrong drug rather than wrong timing"
#ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v
Aurelie Najm AurelieRheumo ( View Tweet)
New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi)
Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough
But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx
Links:
Mike Putman EBRheum ( View Tweet)
In the SERENA study (n=292), secukinumab reduced PsA incidence to 0.49/100 PY over 5 years in PsO patients with nail involvement, an ~82% drop vs historic non-biologic rates (2.7/100 PY). 98.3% remained PsA-free; PASI 90 achieved in 63%. Abstract#1463 @RheumNow #ACR25 https://t.co/ySOuFJiwge
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Like PEXIVAS steroid taper, this is something we need an online resource to check each time. Its complicated, but feels "right". @RheumNow #ACR25 https://t.co/QAgSQB9XMQ
Richard Conway RichardPAConway ( View Tweet)
#ACR25 SMILE RCT of Incomplete #SLE (ANA+ but not meeting SLICC) showed HCQ didn’t slow down SLE progression. But multiplex arrays showed reduction in autoantibodies with HCQ that were distinct from abs assoc. w progression. Would biomarker endpoints be the answer? @RheumNow https://t.co/XcvacgObVo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Beyond biologics: RA meets bioelectric medicine.
In RESET-RA, TNFi inadequate response or intolerant (n=124), vagus nerve stimulation led to significant & durable improvement
🔹 ACR20 3mo: 42% active vs 18% sham (p=0.0057)
🔹 Benefits through 12mo
@RheumNow #ACR25 A#1675
Jiha Lee JihaRheum ( View Tweet)
In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation
Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation
Leflunomide protective? Have others seen this?
#ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv
Mike Putman EBRheum ( View Tweet)
This study evaluated effectiveness of SEC in PsA prevention of a subgroup of pts from SELENA: PsO pts w/o PsA & nail dse (n=292)
At 5 yrs:
🎯98.3% didn't develop PsA (yEAIR 0.49)
🎯 Sustained PASI, PGA 0/1
💡Longterm SEC effective for PsA prevention?
#ACR25 @RheumNow Abs1463 https://t.co/t7P1Oerbrw
sheila RHEUMarampa ( View Tweet)
